Home Apoptosis SMARCA2

SMARCA2

Other Apoptosis Related Inhibitors

Caspase Bcl-2 p53 Ferroptosis PD-1/PD-L1 Survivin TNF-alpha MDM2/MDMX KRas IAP
Cat.No. Product Name Information Product Use Citations Product Validations
E1103 AU-15330 AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4, which can induce potent inhibition of tumor growth in xenograft models of prostate cancer.
EMBO J, 2024, 10.1038/s44318-024-00206-1
E0111 BRM/BRG1 ATP Inhibitor-1 (BRM014) BRM/BRG1 ATP Inhibitor-1 (Compound 14) is an orally active inhibitors of Brahma Homolog (BRM)/SMARCA2 (BRG1) with IC50s below 0.005 µM.
DNA Repair, August 2025, 103884
Chem Sci, 2023, 14(8):2168-2182
S9612 ACBI1 ACBI1 is a potent and cooperative PROTAC degrader of SMARCA2, SMARCA4 and PBRM1 with DC50 of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 induces anti-proliferative effects and apoptosis.
Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2054
Cancer Research, 2025, 1997-2013
Mol Metab, 2025, 93:102107
E6700New G-6599 G-6599 is a potent monovalent degrader of SMARCA2/SMARCA4 that covalently binds a cysteine on E3 ligase FBXO22, forming a ternary complex for ubiquitin-proteasome degradation. It exhibits potential research applications in androgen-dependent prostate cancer and SMARCA4-mutant non-small cell lung cancer.
E1178 FHD-286 (Camibirstat) Camibirstat (FHD-286) is a BRG1/BRM ATPase inhibitor for the treatment of BAF-related disorders such as acute myeloid leukemia.
E0449 SGC-SMARCA-BRDVIII

SGC-SMARCA-BRDVIII is a potent and selective SMARCA2/4 BRD inhibitor.
E1711 FHT-1015 FHT-1015 is a potent, small-molecule, allosteric inhibitor of SMARCA4/SMARCA2 ATPase with IC50 values ≤10 nM. FHT-1205 decreases PD1+TIM3+ cells and cytokine expression in vivo.
S7315 PFI-3 PFI-3 is a selective chemical probe for SMARCA bromodomains, including SMARCA2, SMARCA4 and PB1(5) bromodomains.
bioRxiv, 2025, nan
Cell Rep, 2023, 42(2):112097
J Transl Med, 2023, 21(1):639
Verified customer review of PFI-3
E8293New YD54 YD54 is a potent, selective and orally bioavailable PROTAC and a degrader of SMARCA2 with DC50 of 8.1 nM at 24 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer.
E8294New YDR1 YDR1 is a potent, selective and orally bioavailable Cereblon-based PROTAC and a degrader of SMARCA2 with DC50 of 60 nM at 48 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer.